Cyanosis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cyanosis}} {{CMG}}; {{AE}} ==Overview== ==Epidemiology and Demographics== ===Incidence=== *The incidence/prevalence of [disease name] is approximately [number r...")
 
No edit summary
Line 6: Line 6:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
The reported prevalence of CHD at birth ranges from 6 to 13 per 1000 live births [13-19]. Variation is primarily due to the use of different methods to detect CHD (ie, fetal echocardiography versus postnatal referral to a cardiac center) [17,20].
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.


===Prevalence===
The most common congenital heart defect is a bicuspid aortic valve (BAV), with a prevalence estimated between 0.5 and 2 percent, but as an isolated lesion it is rarely diagnosed in infancy [21-23]. The next most common defects are ventricular septal defects (VSDs) and secundum atrial septal defects (ASDs, prevalence of 4 and 2 per 1000 live births, respectively) [11,15,24,25]. Tetralogy of Fallot (TOF) (figure 2) is the most common cyanotic CHD (0.5 per 1000 births) [15,26].
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
CHD is the leading cause of perinatal and infant death from a congenital birth defect, although outcomes have significantly improved with the advancement of corrective or palliative interventions [1,16,27-29].
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
Critical CHD accounts for approximately 25 percent of all CHD [12]. In infants with critical CHD, the risk of morbidity and mortality increases when there is a delay in diagnosis and timely referral to a tertiary center with expertise in treating these patients [9].
*Patients of all age groups may develop [disease name].
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].
 
===Race===
*There is no racial predilection to [disease name].
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==

Revision as of 18:41, 11 March 2018

Cyanosis Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cyanosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cyanosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cyanosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cyanosis epidemiology and demographics

CDC on Cyanosis epidemiology and demographics

Cyanosis epidemiology and demographics in the news

Blogs on Cyanosis epidemiology and demographics

Directions to Hospitals Treating Cyanosis

Risk calculators and risk factors for Cyanosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

The reported prevalence of CHD at birth ranges from 6 to 13 per 1000 live births [13-19]. Variation is primarily due to the use of different methods to detect CHD (ie, fetal echocardiography versus postnatal referral to a cardiac center) [17,20].

The most common congenital heart defect is a bicuspid aortic valve (BAV), with a prevalence estimated between 0.5 and 2 percent, but as an isolated lesion it is rarely diagnosed in infancy [21-23]. The next most common defects are ventricular septal defects (VSDs) and secundum atrial septal defects (ASDs, prevalence of 4 and 2 per 1000 live births, respectively) [11,15,24,25]. Tetralogy of Fallot (TOF) (figure 2) is the most common cyanotic CHD (0.5 per 1000 births) [15,26].

CHD is the leading cause of perinatal and infant death from a congenital birth defect, although outcomes have significantly improved with the advancement of corrective or palliative interventions [1,16,27-29].

Critical CHD accounts for approximately 25 percent of all CHD [12]. In infants with critical CHD, the risk of morbidity and mortality increases when there is a delay in diagnosis and timely referral to a tertiary center with expertise in treating these patients [9].

References

Template:WH Template:WS